Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.
Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.
In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.
Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.
Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.
Viatris Inc. (NASDAQ: VTRS) and Mapi Pharma announced the presentation of recent clinical findings regarding GA Depot at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston from April 22-27, 2023. The pivotal Phase III clinical trial analyzes the efficacy and safety of GA Depot, a long-acting glatiramer acetate for treating relapsing forms of multiple sclerosis (RMS). Viatris emphasizes its commitment to improving healthcare access for MS patients through innovative solutions. The poster session details include research results to be presented on April 24, 2023, from 5:30 to 6:30 p.m. EST.
Viatris is dedicated to providing high-quality medicines globally, with a portfolio of over 1,400 approved molecules across various therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2023 financial results on May 8, 2023, before the markets open. CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast at investor.viatris.com or by calling 800-579-2543. A replay will also be available on their website. Founded in November 2020, Viatris focuses on providing access to medicines globally. The company operates in over 165 countries and boasts a portfolio of more than 1,400 approved medicines across a wide range of therapeutic areas.
FAQ
What is the current stock price of Viatris (VTRS)?
What is the market cap of Viatris (VTRS)?
What is Viatris Inc.?
What products does Viatris offer?
What are Viatris' key therapeutic areas?
What recent collaborations has Viatris announced?
How did Viatris perform financially in 2023?
Where is Viatris headquartered?
What is YUPELRI®?
What is the significance of RYZUMVI™?
What is the mission of Viatris?
How many people does Viatris employ?
